UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 176 filers reported holding UNIQURE NV in Q2 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $9,603,000 | +3.9% | 300,000 | 0.0% | 0.04% | +18.4% |
| Q2 2021 | $9,240,000 | -8.6% | 300,000 | 0.0% | 0.04% | -24.0% |
| Q1 2021 | $10,107,000 | -6.8% | 300,000 | 0.0% | 0.05% | -23.1% |
| Q4 2020 | $10,839,000 | -34.6% | 300,000 | -33.3% | 0.06% | -43.5% |
| Q3 2020 | $16,574,000 | +22.6% | 450,000 | +50.0% | 0.12% | +6.5% |
| Q2 2020 | $13,518,000 | +14.0% | 300,000 | +20.0% | 0.11% | +5.9% |
| Q1 2020 | $11,863,000 | -17.2% | 250,000 | +25.0% | 0.10% | +5.2% |
| Q4 2019 | $14,332,000 | +260.8% | 200,000 | +98.2% | 0.10% | +223.3% |
| Q3 2019 | $3,972,000 | -49.2% | 100,922 | +0.9% | 0.03% | -41.2% |
| Q2 2019 | $7,815,000 | +1587.9% | 100,000 | +100.0% | 0.05% | +628.6% |
| Q3 2014 | $463,000 | -31.9% | 50,000 | 0.0% | 0.01% | -30.0% |
| Q2 2014 | $680,000 | -12.7% | 50,000 | 0.0% | 0.01% | -33.3% |
| Q1 2014 | $779,000 | – | 50,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |